What the FDA labels say about taking them together
Oritavancin and warfarin
Oritavancin's FDA label of December 18, 2025 names warfarin in its drug interactions section; the warfarin label PlainMeds reads does not name oritavancin. The oritavancin label: “Patients should be closely monitored for signs of toxicity or lack of efficacy if they have been given KIMYRSA while on a potentially affected compound.”
Check it at the source: the oritavancin FDA label on DailyMed (effective December 18, 2025, Melinta Therapeutics, LLC); the warfarin FDA label on DailyMed (effective May 29, 2026, Amneal Pharmaceuticals LLC).
What does the oritavancin label say about warfarin?
Oritavancin label, drug interactionsPatients should be closely monitored for signs of toxicity or lack of efficacy if they have been given KIMYRSA while on a potentially affected compound (e.g., patients should be monitored for bleeding if concomitantly receiving KIMYRSA and warfarin).
Oritavancin label, warnings and precautionsEvaluate patients if diarrhea occurs. ( 5.4 ) Concomitant warfarin use: Oritavancin has been shown to artificially prolong PT/INR for up to 12 hours ( 5.1 ).
Source: FDA drug label (Orbactiv, NDA206334), Melinta Therapeutics, LLC, effective July 17, 2025 (SPL set ff09a726-9f9b-4e30-b509-396781293220), via openFDA
Source: FDA drug label (Kimyrsa), Melinta Therapeutics, LLC, effective December 18, 2025 (SPL set 5e755c40-6e73-4572-b474-4d8a131693d1), via openFDA; the full label on DailyMed
What does the warfarin label say about oritavancin?
Warfarin's label (effective May 29, 2026) does not name oritavancin in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Warfarin Sodium), Amneal Pharmaceuticals LLC, effective May 29, 2026 (SPL set 558b7a0d-5490-4c1b-802e-3ab3f1efe760), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Oritavancin | Warfarin | |
|---|---|---|
| Labeled for | n/a | Blood clots (DVT and PE), Atrial fibrillation |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.093 per tablet 2 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once